(Q33761460)

29 July 2017

The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals (English)

1 reference

29 July 2017

Glennie JL

1

1 reference

29 July 2017

Torrance GW

2

1 reference

29 July 2017

Baladi JF

3

1 reference

29 July 2017

Berka C

4

1 reference

29 July 2017

Hubbard E

5

1 reference

29 July 2017

Menon D

6

1 reference

29 July 2017

Otten N

7

1 reference

29 July 2017

Rivière M

8

1 reference

29 July 2017

1 May 1999

1 reference

29 July 2017

1 reference

29 July 2017

15

1 reference

29 July 2017

5

1 reference

29 July 2017

459-468

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199915050-00004

29 July 2017

0 references

cites work

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

1 reference

12 December 2020

Managed care pharmacy, socioeconomic assessments and drug adoption decisions

1 reference

12 December 2020

Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions

1 reference

12 December 2020

Data sources for pharmacoeconomic and health services research.

1 reference

12 December 2020

A radical rupture in the paradigm of modern medicine: conflicts of interest, fiduciary obligations, and the scientific ideal

1 reference

12 December 2020

Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

1 reference

12 December 2020

The Danish approach to standards for economic evaluation methodologies.

1 reference

12 December 2020

The emerging government requirement for economic evaluation of pharmaceuticals

1 reference

12 December 2020

Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems, and public policy

1 reference

12 December 2020

Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.

1 reference

12 December 2020

Making economic evaluations respectable

1 reference

12 December 2020

Industry comment on the 1995 revised Australian pharmacoeconomic guidelines

1 reference

12 December 2020

The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals

1 reference

12 December 2020

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

12 December 2020

Ethical issues in the economics of rationing healthcare

1 reference

12 December 2020

Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics

1 reference

12 December 2020

Ethics and economics. Antagonists or allies in making health policy?

1 reference

12 December 2020

Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada

1 reference

12 December 2020

Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.

1 reference

12 December 2020

Use of economic evaluation guidelines: 2 years' experience in Canada

1 reference

12 December 2020

Pharmacoeconomics and the quality of decision-making by pharmacy and therapeutics committees

1 reference

12 December 2020

Economic evaluation of drugs and its potential uses in policy making

1 reference

12 December 2020

10.2165/00019053-199915050-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1026213389

0 references

Fatcat ID

release_tbr6gkhjw5ekzegz3lujyx5vyy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tbr6gkhjw5ekzegz3lujyx5vyy

24 November 2022

mapped directly with Wikidata item

1 reference